GSK reports 76% complete response in rectal cancer and 62% response in ovarian cancer trials
GSK announced interim results from its phase II AZUR‑1 trial showing that 76% of evaluable patients with MSI‑H/dMMR rectal cancer achieved a complete response to Jemperli, with 68% sustaining the response for at least 12 months. In a separate phase I BEHOLD‑1 study, the investigational antibody‑drug conjugate Mo‑Rez produced a confirmed response in 62% of ovarian‑cancer patients, with median response duration of 12.2 months. The data were presented at the ESMO Congress and support the recent U.S. approval of Jemperli for this indication.
Why it matters
GSK says the Jemperli results could allow some patients to avoid chemotherapy, radiation and surgery, expanding the drug’s market potential. The Mo‑Rez response rate and durability suggest a promising new therapy for platinum‑resistant ovarian cancer, which may drive future sales.
Key facts
- 1In the AZUR‑1 phase II trial, 110 of 144 evaluable rectal‑cancer patients (76%) had a complete response to Jemperli. investing.com
- 2Of those responders, 98 patients (68%) maintained a clinical complete response for at least 12 months without surgery. themarketreporter.co.uk
- 3Independent central review showed 54 of 116 evaluable patients (47%) had reached a 12‑month sustained response at the time of analysis. themarketreporter.co.uk
- 4Serious adverse reactions occurred in 20% of AZUR‑1 patients, and 3% stopped treatment because of side effects. investing.com
- 5In the BEHOLD‑1 phase I trial, 28 of 45 ovarian‑cancer patients (62%) achieved a confirmed response to Mo‑Rez at the 5.8 mg/kg dose selected for phase III. asktraders.com
- 6Median duration of response in the Mo‑Rez study was 12.2 months and median progression‑free survival was 11.1 months. asktraders.com
Open questions
- Conflicting reports on share‑price movement: down 1.04% to 1,894 pence versus up 1.1% to 1,914.50 pence.
Summary written by AlphAI AI Desk from 5 of 5 sources. Not investment advice. Figures are as stated by the linked sources.